IGA NEPHROPATHY (IGAN)
Clinical trials for IGA NEPHROPATHY (IGAN) explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY (IGAN) trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for kidney disease in early trial
Disease control CompletedThis study tested a new tablet called HSK39297 in 87 adults with IgA Nephropathy, a kidney disease. The goal was to see if it could reduce protein in the urine, a sign of kidney damage, compared to a placebo. The trial lasted 12 to 24 weeks and aimed to check both safety and effe…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
Brain-Gut-Kidney link may explain memory loss in kidney disease patients
Knowledge-focused CompletedThis study looked at why people with IgA nephropathy (a kidney disease) often have trouble with memory and thinking. Researchers used advanced brain scans and analyzed gut bacteria and blood samples from 100 patients and 100 healthy people. The goal was to find connections betwee…
Matched conditions: IGA NEPHROPATHY (IGAN)
Sponsor: Tang-Du Hospital • Aim: Knowledge-focused
Last updated Jun 16, 2026 22:19 UTC